 6. Participants must have developed progressive disease after receiving prior therapy and must have an interval of at least 12 weeks from the completion of radiation and concomitant temozolomide therapy to study entry unless progressive tumor growth is outside the radiation field or there is histopathological confirmation of recurrent tumor 